CORTICOSTEROID THERAPY IN CURRENT DERMATOLOGICAL PRACTICE

H. W. CHADFIELD, M.R.C.P.E.
Consultant Dermatologist, Wolverhampton, West Bromwich, Dudley and Stourbridge Groups of Hospitals

The introduction of corticosteroid drugs in 1949, thanks to the pioneer work of Kendall, Reichstein and Winterstein, ranks as one of the greatest medical advances of all time and probably the greatest since antibiotics were discovered a couple of decades ago. In no other field, probably, has their application been of greater service than in dermatology, and they have now been employed long enough for a reassessment of their worth.

Under the influence of the pituitary adrenocorticotropic hormone, which is probably under hypothalamic control, a variety of steroids is secreted by the adrenal gland including hydrocortisone (or cortisol), corticosterone, aldosterone and sex hormones like progesterone, estrogen and androgens. There is a reciprocal relationship between the concentration of circulating corticotrophin and of adrenal cortical hormones. Hydrocortisone, which like corticosterone and cortisone belongs to the 11-oxysteroid group of adrenal corticosteroids—so called because an = O or -OH group is attached to C in the 11 position—is secreted by the human adrenal cortex in far greater amounts than any of the other hormones. Cortisone, the first of the synthetic corticosteroids to be manufactured, is not produced by the adrenal gland, and when administered therapeutically is probably converted into hydrocortisone which is the active hormone. In recent years several hundred analogues of cortisone have been prepared by inserting additional groups into the parent structure in an attempt to eliminate undesirable mineralocorticoid sodium retaining and potassium losing effects by virtue of the lower dosage required, but the perfect analogue has yet to be discovered. The introduction of double bonds between 1 and 2 carbon atoms in ring A produced the more potent prednisone and prednisolone. The attachment of a fluorine atom to the 9C position yielding fludrocortisone further enhanced the anti-inflammatory effect while adding a hydroxyl or a methyl group to the latter reduced sodium retention and produced triamcinolone and dexamethasone respectively. More recent additions are betamethasone and paramethasone.

Pharmacological Effects
A thorough understanding of the metabolic effects of these agents is essential for their proper clinical use and for the minimization of undesirable side reactions. The corticosteroids employed therapeutically are generally called glucocorticoids because of their easily observed effects on carbohydrate metabolism. They raise the blood sugar level by decreasing the utilization of glucose, by converting amino acids into glucose (gluconeogenesis) and possibly also by hindering the tubular reabsorption of glucose. Thus their effect is diabetogenic and when they are present in excess, hyperglycemia, glycosuria and impaired glucose tolerance may result.

Their effect on protein metabolism may be catabolic or anti-anabolic with interference with protein synthesis. A negative nitrogen balance results with accompanying retardation or cessation of growth, muscle wasting, thinning of the skin, defective tissue repair, striae, spontaneous bruising and osteoporosis.

Lipid metabolism is affected, there being a redistribution of body fat with an accumulation on the face ('moon face') and a deposition on the nape of the neck ('buffalo hump') and the abdomen at the expense of fat in the extremities as in Cushig's syndrome.

The mineralocorticoid fraction influences electrolyte and water metabolism promoting the retention of sodium and the excretion of potassium. Edema, hypertension and heart failure may ensue.

A negative calcium balance from increased fecal excretion and an abnormal phosphate loss may lead to osteoporosis and vertebral collapse. There is some evidence suggesting that adrenal corticosteroids are antagonistic to Vitamin D. The blood components are influenced, the number of circulating eosinophils and lymphocytes being reduced, while polycythemia may occur.

Mode of Action and Therapeutic Effects
To many patients the corticosteroid must indeed seem the wonder drug of this age, but nature exacts a high price for the apparent miracle and corticosteroids are a double-edged weapon with a power for evil as well as for good.

The corticosteroids are apparently simple substances chemically and though their action at the molecular or even cellular level remains unexplained, they are thought possibly to be co-factors essential to enzymic reactions, the catalytic action being probably at a physical rather than a chemical level. The pharmacological use of these drugs implies the employment of unphysiological doses and depends on the production of a state of hypercorticalism.

Corticosteroids and corticotrophin neither cure the condition in which they are employed nor do they eradicate the cause of the disease nor repair damaged tissue. Their therapeutic effects stem from their anti-inflammatory and anti-allergic actions. In large amounts they suppress the manifestations of inflammatory reactions, relieving the hyperemia, edema and exudation and reducing the formation of granulation tissue. It is fortunate that this suppression of signs and symptoms of disease does not appear to interfere with any of the natural self-healing processes of the illness, and in the treatment of ordinarily fatal conditions one endeavours to keep the patient alive long enough, one hopes, to enable the pathological process to burn itself out. Manifestations of allergic reactions including delayed hypersensitivity responses such as the Arthus phe-
nomenon, the tuberculin and Frei reactions, vasculitis and serum sickness, but excepting the immediate skin reaction to injected allergen, are suppressed, the beneficial effects being effected neither by any antagonism of the pharmacological actions of histamine or of 5-hydroxytryptamine nor by any inhibition of the antigen—antibody reaction, but probably by a blockage of the effects of histamine on the tissues and by an effect on capillary permeability. The active formation of antibodies (active immunity) is suppressed, whereas there is no effect on injected antibodies (passive immunity).

Cutaneous effects of corticosteroid therapy include also follicular hyperkeratization, decreased formation of sebum and increased sweating. As already stated the skin participates in the depletion of body protein, becoming atrophic and fragile and striae may occur from thinning of collagenous and elastic fibres. Purpura may occur from collagen degeneration as in senile purpura. Dorfman and Schiller (1958) have shown that the consistency and permeability of the intercellular ground substance of connective tissue is involved, the metabolism of its mucopolysaccharide constituent being reduced. Corticotrophin may cause pigmentation (probably from contamination with the melanin-stimulating hormone of the pars intermedia) and spider naevi.

Hazards of Systemic Therapy

Many of the hazards have been implicit in the consideration of the metabolic effects. The list is impressive and equalled probably by no other drug.

Side effects, or therapeutically undesirable but inevitable and unavoidable effects, of these drugs result from high dosage employed over a short period of time or more frequently, from moderate doses given over some weeks or months. The result from excess of hormone and present as varying degrees of Cushings Syndrome. Nearly all patients receiving a dose of the order of 15 mg. of prednisolone daily will in time develop one or other of these. They include moon face, buffalo hump, striae, oedema, hypertension, congestive cardiac failure, the unmasking of latent diabetes or the aggravation of existing diabetes, osteoporosis (including crush fractures of the spine), psychosis (resulting in emotional changes, depression, disorientation, hypomania or suicidal tendencies), androgenic manifestations (acne, hirsutism and amenorrhoea, probably from imputities) and developmental abnormalities when administered during pregnancy.

Toxic effects are not seen from the true hormone itself but may appear following the use of the usual analogues. 'Primary myopathy' with muscle damage involving proximal muscle groups of the limbs was described by Williams (1959) following the use of triamcinolone and dexamethasone. Other possible toxic effects from triamcinolone are headache, dizziness, anorexia, loss of weight and telangiectasia of the face, trunk and limbs.

The recently evidence has been presented to support the contention that a moderate or high dose of corticosteroid therapy over a prolonged period of time may cause posterior subcapsular lens opacities (Black, Ogelsby, Von Smallman, and Bunin (1960)).

Altered tissue reactions may cause enhancement of infective processes (e.g. the aggravation of pre-existing infections like tuberculosis or, as shown by Goldstein and Rambo (1962), cryptococcosis, and the masking of symptoms and signs of infection) and delayed wound healing. Activation of peptic ulceration (aided probably by an increased secretion of hydrochloric acid, pepsinogen and trypsinogen and by a local interference with the replacement of gastric mucosa continually shed in the normal process of exfoliation) may cause perforation and haemorrhage, and perforation of the colon may occur in cases of diverticulitis. There may be a liability to vascular thrombosis and thrombo-embolic complications possibly from inhibition of fibrolsins.

Corticosteroid withdrawal. It is well known that the abrupt termination of a course of corticosteroid therapy may be followed by adrenocortical atrophy from suppression of corticotrophin production, through recent work by Treadwell, Savage, Seyer and Copeman (1963) suggests that this atrophy is never complete and stresses the failure of pituitary response to subnormal levels of circulating hydrocortisone.

Abrupt cessation of treatment or the supervision of a state of relative insufficiency (as when the increased requirements of a stressful situation are not met) may also, paradoxically, produce arteritis and other manifestations of damage to connective tissue and result in a condition resembling naturally occurring polyarteritis nodosa or systemic lupus erythematosus (S.L.E.) which may be superimposed on a pre-existing collagenosis.

In one series of cases Nordin (1960) reported that death attributable to corticosteroid therapy occurred in 8% while a M.R.C. review (1961) of 107 patients with S.L.E. treated with steroid hormones over a period of at least two years showed that complications attributable to this treatment included 16 occurrences of hypertension, nine of psychotic change, five of infection, four of gastro-intestinal haemorrhage, two each of crushed fractures of vertebræ, dyspepsia and hirsutism and one of glycosuria.

Contra-indications

Systemic corticosteroid therapy should be withheld in Cushings syndrome, peptic ulceration, diverticulitis, psychoses, chronic nephritis and in infections insusceptible to antibiotics.

It should, when required, be administered with caution in cardiovascular disease, diabetes mellitus, osteoporosis, pregnancy, thrombotic diseases and where a psychiatric case history exists.

In general, contra-indications are less likely to be binding, and benefit more likely to ensue, in the case of severe acute and short lived conditions than in persistent disorders.

Routine precautions

It follows that the taking of a careful personal family history and a complete general medical examination are pre-requisites for a decision on the employment of these drugs. The examination must include a recording of the blood pressure and weight and an analysis of the urine and must be repeated weekly while the patient remains under treatment. In addition an X-ray must be taken of the chest to exclude active or latent tuberculosis and of the skeleton (and repeated at intervals of four months while under risk) to exclude osteoporosis, where a history of the employment of these drugs is a barium meal. Serum sodium and potassium estimations may be required and routine ophthalmological examinations have been suggested for some cases.

Steroid tablets should be chewed with a meal or, especially when there is a history of dyspepsia, be dispensed in enteric-coated form. Antacids may be required. It is customary to administer potassium supplements (e.g. 1 g. potassium chloride t.d.s.). When osteoporosis is present and steroid treatment is considered essential, further drain on bone calcium may be minimized by the daily administration of 3 g. of calcium, 50,000 units of Vitamin D and of an anabolic steroid (e.g. norethandrole 30 mg.).

A warning card giving the patients name and address and the dosage of treatment should be carried by him.
at all times to guard against interrupted dosage and to ensure that the increased demands of any stressful situation (e.g. accident, infection or operation) are met.

**Dosage and Methods of Employment**

The initial dosage required to bring a condition under control may vary from as little as 15 mg. of, say, prednisolone a day in divided doses in a simple benign disorder like eczematous dermatitis to as much as 400 mg. daily in divided doses for a severe fatal condition like pemphigus vulgaris. In general, the former type of case requires a dose in the region of 30 or 40 mg. of the aforementioned drug (or equivalent dose if a different analogue is used) daily at the commencement of therapy while an average initial requirement in the latter group is 80 mg. daily. The assessment of the appropriate dose is a matter of judgement based largely on experience. Some aim at a dosage which is a little above the minimum required for suppressive action while others prefer to feel their way more cautiously with smaller doses which may have to be increased rapidly and sometimes even doubled to achieve control.

The disease having been brought under control, the dose should be gradually reduced to the amount which is necessary to keep the patient comfortable and usually to below the level required to suppress the symptoms entirely. After a further period of time an attempt at slower reduction with decrements of 5 mg. or less of this drug every three or four days is made. If control is lost the dose may have to be increased temporarily to above the level from which it was last reduced after which a further attempt at lowering it is undertaken. The secret of success in dose reduction is patience and it can sometimes be obtained by subtracting as little as 1 mg. from the daily dose at intervals of 3 or 4 days, achieving the desired object almost by stealth as it were. The 1 mg. tablets of prednisolone are particularly helpful in this respect.

The maintenance level is usually between 10 and 15 mg. a day but may vary between 5 and 30 mg. or more daily depending upon the severity of the condition and probably other factors as well.

The reduction of the dose to the lowest possible level and the eventual discontinuation of the drug whenever possible must always be the physician's set aim and purpose.

**Indications for Systemic Treatment**

It is obvious that the decision whether or not to employ corticosteroids systemically involves a careful appraisal of all relevant circumstances, considering the risks involved against the likely benefits. At all times it is a calculated risk comparable at least, in my opinion, to the hazard of a laparotomy and probably far greater. Yet, under the relentless pressure of propaganda from drug firms, and sometimes because of the insistence of the patients themselves, there is a growing tendency to use these drugs, often in inadequate dosage, for conditions which are either insensitive to them or which, if amenable to their action, could be treated far more safely and adequately by more conventional methods. Particularly to be condemned is their employment, sometimes in panic fashion, before a diagnosis has been made. The rash is then partially or completely suppressed, rendering the condition virtually undiagnosable and its management complicated, to say the least. Worse still is the suppression, not only of the rash but of the vitally important information that these drugs have been used. In the words of Sulzberger and Wolf (1952), anyone who prescribes or administers these drugs lightly is not living up to his responsibilities as a physician.

In actual fact, the indications for systemic treatment are fairly clear and there are, broadly, three main groups of conditions which may be benefited.

**Severe disorders threatening life**

The collagenoses. Diseases characterized by fibrinoid degeneration of connective tissue and believed to be auto-immune disorders in view of the presence in the serum gammaglobulin fraction of antibodies to a large number of autologous tissue components.

- Acute systemic lupus erythematosus (S.L.E.)
- Dermatomyositis
- Polyarteritis nodosa
- Vesico-bullous diseases. The pemphigus group of diseases (pemphigus vulgaris, pemphigus vegetans, pemphigus foliaceous and pemphigus erythematosus), pemphigoid and benign mucous membrane pemphigoid (ocular pemphigus), severe erythema multiforme (including Stevens-Johnson syndrome).
  - Epidermolysis bullosa (severe dystrophic variety)
  - Toxic epidermal necrolysis (Lyell)
  - Herpes gestationes
- Exfoliative erythrodermia
- Severe anaphylactoid purpura
- Rarer miscellaneous dermatoses
  - Pyoderma gangrenosum
  - Recurrent febrile non-suppurative panniculitis—(Weber-Christian)
  - Lethal midline granuloma of the face
  - Wegener's respiratory granulomatosis
  - Certain reticulooses and reticulo-endothelioses
  - Certain lepromatous reactions

**Severe acute self-limiting eruptions**

Severe sensitization or contact dermatitis
Severe drug eruptions
Acute widespread lichen planus (including lichen planus bullous)
Severe angioneurotic œdemata with laryngeal involvement
Acute radio-dermatitis

**Severe exacerbations of chronic eczema** *(e.g. in atopic eczema)*

*Systemic Lupus Erythematosus.* There is general agreement that steroids should be reserved for seriously ill patients and not used in the benign phases of this condition. Initial doses of the order of 50 or 60 mg of prednisolone daily are likely to be required and may have to be increased should a rapid therapeutic response not occur. Doses of up to 400 mg daily of this drug may, on occasion, be necessary in case of a crisis. Under the influence of corticosteroid therapy, subjective improvement occurs in the first week and objective findings like pleural and pericardial effusions clear shortly afterwards, though cutaneous lesions are slower to resolve, taking up to a month. Unfortunately, renal disease remains unaffected. Objective findings like leucopenia, hyperglobulinemia and elevation of the ESR tend to improve though they by no means invariably return to normal and the ESR is not a reliable guide to dosage. The characteristic L.E. cells, formed by the phagocytosis by polymorphonuclear leucocytes of extruded degenerate nuclear material of other polymorphs with the production of swollen cells containing a large basophilic amorphous inclusion body and an eccentric nucleus, likewise tend to become fewer, but rarely disappear completely.

Once a remission has been induced the drug should be gradually discontinued if possible, or reduced to a suitable maintenance level below which signs of activity begin to appear. The dosage may thereafter have to be increased in case of a relapse.

Despite the effectiveness of steroids in this condition it is, as yet, uncertain how far the eventual outcome is influenced and the prognosis remains grave.

*Dermatomyositis.* This condition belongs to the category of polymyositis, a composite group of degenerative muscular disorders characterized by muscular weakness or paralysis and sometimes symptomatic of a visceral or other neoplasm.

Some cases, especially of the juvenile type, are responsive to steroids and the requirements approximate those of an average case of S.L.E. though a particularly careful watch must be maintained on the nitrogen balance because of the considerable breakdown of muscle protein in this disease.

*Polyarteritis Nodosa.* The cutaneous manifestations of this condition may be eruptions of scarlatiform, urticarial, vesicular or bullous character or ulcerations. Prednisolone in a dose of 60 to 100 mg daily may be required initially and a prolonged maintenance dosage is usually necessary. There is some danger that rapid healing of the lesions may be accompanied by arterial occlusion.

*Progressive Systemic Sclerosis* *(Diffuse Scleroderma)* is not usually an indication for systemic corticosteroid therapy in view of the reported supervision of malignant hypertension and uremia in cases so treated.

*The Pemphigus* group of diseases (particularly pemphigus vulgaris) and the less lethal conditions of pemphigoid and benign mucous membrane pemphigoid (ocular pemphigus) are greatly benefited by systemic steroid treatment with general constitutional improvement and a diminution in the rate of bulla formation within forty-eight hours and a cessation of their appearance usually within a week. A relatively high dosage of usually at least 60 mg of prednisolone daily, and sometimes considerably more, is required initially in the pemphigus group and must be rapidly doubled if ineffective to prevent loss of control.

Recently Lever and White (1963) stress the importance of early treatment with initial high doses and advocate a daily dose of 24 tablets of 5 mg. of prednisolone for mild cases and 36 tablets of the drug for cases showing more extensive involvement with increase of dosage to 36 or 48 tablets respectively should new lesions continue to appear after 5 days. The requisite dosage is continued for 6 to 8 weeks until healing is complete and then reduced in stages over a period of some months to the lowest possible maintenance dose.

In one series of cases the mortality with steroids, though still considerable, was reduced to one third of what it was in the pre-steroid era. Pemphigoid is more easily controlled and smaller doses, e.g. 40 mg daily initially, may be effective.

*Erythema Multiforme.* This is a syndrome due to multiple causes (e.g. drugs, focal bacterial infection, viruses, reticuloses, etc.) and an attempt to establish a concise aetiological diagnosis is essential before a therapeutic decision is made. Steroids may be required in the severe form associated with mucosal (e.g. conjunctival, oral, genital) lesions, and known as the Stevens-Johnson syndrome.

*Behçet's Triple-Symptom Complex* of recurrent genital and oral ulceration with associated eye lesions and at times erythema-multiforme-like eruptions may be benefited.

*Epidermolysis Bullosa.* A hereditary and familial condition characterized by a vulnerability of
the skin to trauma with the formation of vesicles and bullae, usually over bony prominences of the extremities. Systemic corticosteroids may be of value in the severe dystrophic and lathal forms of the disease which may involve the oropharyngeal and oesophageal mucosa with resultant bulla formation, ulceration, scarring, and sometimes stenosis of the upper alimentary tract.

**Toxic Epidermal Necrolysis (Lyell).** This acute fulminating febrile disturbance which appears as an inflammation of mucous membranes and a rapidly spreading erythema with ensuing blistering, loosening and shedding of the superficial layers of the skin, produces a characteristic scalded appearance and is frequently a manifestation of drug intoxication (as from phenolphthalein, phenylbutazone or gold) and may respond to corticosteroid therapy.

**Herpes Gestationis.** Steroids may on occasion be justified in this variant of dermatitis herpetiformis which is associated with pregnancy.

**Exfoliative Dermatitis,** whether primary, complicating a pre-existing dermatosis (like eczema, psoriasis, seborrhoeic dermatitis or lichen planus), a form of drug reaction or a manifestation of a reticulosis may require the hormone systemically.

**Pyoderma Gangrenosum.** This sometimes alarmingly progressive ulcerative condition of the skin which is sometimes associated with ulcerative colitis is, in my experience, frequently responsive to systemic steroid therapy.

**Weber-Christian disease** is a recurrent febrile non-suppurative nodular inflammatory disorder of adipose tissue involving the subcutaneous and, on occasion, also the omental, mesenteric and other adipose tissues with subsequent fat necrosis. Steroids may be of value (though a fatal case with visceral involvement of which I have personal knowledge, did not respond) and hence it has been suggested that this may be a collagen adisease.

**Lethal Midline Granuloma of the face,** characterized by a progressive destruction of the centre of the face with ulceration and necrosis and the allied Wegener's respiratory granulomatosis, a necrotizing vasculitis of the lungs and skin with glomerulonephritis (which may be a variant of polyarteritis nodosa) are indications for the use of systemic corticosteroid therapy.

**The Reticuloses.** Oral steroids may relieve some of the cutaneous manifestations of acute and chronic leukaemia, of Hodgkin's disease, of mycosis fungoides, and of allied conditions in virtue of their anti-inflammatory and anti-puritic effects.

Certain reticulo-endothelioses like Letterer-Siwe disease of infancy may be benefited.

In **Severe Sensitization and Contact Dermatitis** the cause must always be sought and, once removed, the course of the illness may be considerably curtailed by the systemically administered hormone.

In **Drug Reactions** steroids should be reserved for severe cases only, when other methods of treatment have failed.

When the patient has become sensitive to a vitally needed drug its continued administration may, on occasion, be rendered possible, or desensitization attempted, by concomitant steroid therapy, though these procedures are not without risk.

**Acute Radiodermatitis.** In a recent series (Sweet 1962) of accidentally produced superficial X-ray burns, it was felt that though treatment with large doses of oral prednisolone had no effect in preventing epidermal loss with epilation, it postponed the subsequent necrosis of the dermal and deeper tissues (probably by inhibiting the vascular occlusion resulting from fibrosis of the walls of blood vessels) and appeared to lessen pain and help the maintenance of function.

**Atopic Eczema** calls for special comment. In a very chronic disorder of this nature the patients have, of necessity, learned to live with their disability and this they are prepared to do. When, however, the magic drug capable of causing relief in almost miraculous fashion is exhibited and then subsequently withdrawn, they frequently become intensely depressed, intolerant of the slightest recrudescence and unable to adjust themselves to the new state of affairs. I have found it exceedingly difficult to wean some of these patients from their steroids once effective relief has been obtained and to this extent the drug may be regarded as one of addiction. To borrow a phrase—'We have got a tiger by the tail and we dare not let go'—for on every occasion on which an effort is made to diminish the dosage the patient's skin flares up violently. Nevertheless, some cases of atopic eczema are so severe and disabling and interfere with all the patients activities to such an extent that systemic corticosteroid therapy may become permissible, but one must be prepared to continue minimal suppressive therapy for months or even years if necessary.

Systemic corticosteroids are not advised in **infantile eczema** nor in **psoriasis** (except the erythrodermic type) nor in **alopecia areata.**

**Local Corticosteroid Therapy**

Corticosteroid preparations for topical therapy are now in very wide use and the multiplicity of available preparations equals that of the systemically used drugs and is bewildering.
Hydrocortisone was the first of these to be employed, cortisone and corticotrophin being ineffective topically. Other preparations now contain prednisolone, methyl prednisolone, triamcinolone, dexamethasone, betamethasone or fluorocortisone. It was found that a combination of 16-alpha and 17-alpha hydroxyl groups of triamcinolone with acetone to form the acetonide, greatly increased topical activity. Two new synthetic fluorinated corticosteroids for topical use, fluocinolone (Synalar, I.C.I.) and flurandrenolone (Drenison, Lilly) contain the same acetonide group and are claimed to have greater anti-inflammatory activity.

These preparations vary in strength from 0.025% to 2.5%, largely according to their individual potency. Most of them are available as lotions, creams and ointments and some of them as aerosol sprays. Recently, one of these preparations has become available in emollient dental paste (Adcortyl A in Orobase, Squibb) for the treatment of acute and chronic oral lesions.

Properly used, these preparations are of inestimable value in the treatment of cutaneous diseases, but there is a growing tendency to use them indiscriminately as a first line of attack in unsuitable cases, sometimes undiagnosed, or in conditions which can be treated more effectively and cheaply by other means. Again, it must be stressed that this treatment, as in the systemic variety, is suppressive only and does not cure, and must be preceded by adequate diagnosis and an attempt to find the cause of the illness. Though cases of herpes simplex can be seriously aggravated by such treatment, little harm, fortunately, results as a rule in unsuitable cases—except to the exchequer, for these drugs are still very costly. With the exception of fluorocortisone, systemic absorption of these steroids, administered topically, is believed to occur in minute amounts only, though the new occlusive techniques are likely to facilitate this process.

As in the case of dermatological preparations generally, the base is no less important than the active ingredient and differences in composition probably account for varying therapeutic response and tolerance, sensitization to the corticosteroid being virtually unknown. As a general rule, sprays, lotions and creams are indicated for acute and sub-acute lesions and ointments for chronic conditions.

Corticosteroids applied locally are pleasant to use, do not soil clothing and are effective in virtue of their anti-inflammatory and anti-pruritic effects (they are known to cause vasoconstriction when applied to healthy unbroken skin). Their effectiveness is limited by the thickness of the horny layer of skin and consequently they are more beneficial when applied where the epidermis is thin (e.g. on the eyelids, face and neck) than on such areas as the palms and soles. They should be applied sparingly and rubbed gently into the affected areas three or four times daily. They should not be discontinued abruptly when the condition improves, but applied at longer intervals. Covering dressings are usually unnecessary unless there be friction from clothing.

Almost every known topical corticosteroid preparation is now combined with at least one other active, usually antibacterial, substance. Provided the indications exist, e.g. a microbial or fungal infection complicating eczema, there is no harm and, indeed, benefit to be derived from the combination, but the use of multiple preparations in 'blunderbuss' fashion (as when steroid, antibiotic and potentially sensitizing local anaesthetic preparation are combined) is not advised. I have, however, found one corticosteroid-antibiotic-pancreatic enzymic combination (Chymar ointment, Armour) useful in necrotic slough-covered ulcerative conditions. Other substances usefully combined with corticosteroids are dequaniium chloride (Dequalone P.—A. & H.), domiphen bromide (Ul tacortenol with Bradosol cream, Ciba), iodochlorhydroxyquinoline (Vioform, Ciba) and soframycin with gamicidin (Sofradex, Roussel) the latter being useful in otitis externa.

**Indications**

Topical use of corticosteroid preparations is often effective in the following conditions:—

*Eczema and dermatitis, including atopic eczema, infantile eczema, contact dermatitis, neuro-dermatitis*

*Intertriginous eruptions, e.g. seborrhoeic, involving the axille, groins and retro-auricular spaces (including otitis externa)*

*ANO-genital pruritus*

*Facial and flexural psoriasis*

*Chronic discoid erythematous—preliminary impression seems to indicate that one of the latest preparations (Synalar, in ointment form) may be of great value in this condition. If this can be substantiated it would indeed represent a great advance in the treatment of this cosmetically baneful condition which has hitherto necessitated the use of ophthalmologically dangerous drugs*

*Lichen sclerosus and atrophicus (some cases)*

*Aerosols are not, in general, favoured by most authorities, largely on the grounds of expense, but I have found one corticosteroid-antibiotic preparation in this form (dexamethasone with neomycin—Decaspray, Merck, Sharp & Dohme)*

September 1963

CHADFIELD: Corticosteroid Therapy

531
very useful in infected exudative eczematous conditions.

**Plastic Occlusive Dressings**

These have recently been introduced in this country by Overton (1962) following the example set in the United States by Sulzberger and Witten (1961) and by Scholtz (1961) who adapted the method used by Gärb (1960) in treating hyperkeratotic navi with podophyllin. The corticosteroid cream (e.g. Synalar or Drenison—sometimes mixed, for the sake of economy in widespread lesions, with up to ten times its quantity of ung. aquosum) is applied to the affected areas and covered with thin flexible plastic material such as polythene which is secured and made airtight with cellophane tape. An overlying tubular gauze dressing may be applied. Hall-Smith (1962) has recently reported on the employment of this technique in seventy-two patients suffering from chronic and recalcitrant dermatoses including psoriasis, chronic fissured eczema and pompholyx of the hands, atopic dermatitis, lichen simplex chronicus, pustular bacteride of the soles, hypertrophic lichen planus, keratosis pilaris and ichthyosis simplex. Most of the cases showed rapid improvement though there was a tendency to relapse when the treatment was discontinued. This treatment has also been used in localized scleroderma (morphaea) involving a limb. The dressings are changed every forty-eight hours or more often, depending upon the tolerance of the patient.

The rationale of this method of treatment is the assurance of more intimate contact of the medicament with the lesion and enhanced percutaneous absorption resulting from the increased local sweating and the promotion of epidermal maceration.

Undesirable effects must be guarded against. These include skin infections (folliculitis, boils or abscesses), danger from fire and possible impaired thermal homeostasis.

**Occlusive Hydrocortisone Bandaging**

This addition to the conventional range of occlusive bandages is a more recent development still. Holti and Ingram (1963) recommend the use of cotton bandages impregnated with hydrocortisone in a silicone barrier cream (Smith and Nephew) which can be left in place (covered with e.g. tubular gauze bandages) it is claimed, for up to six weeks. It is apparently particularly useful in cases of infantile eczema.

**Mucosal Application of Corticosteroids**

Triamcinolone acetonide (Adcortyl A) in orobase (a new type of adhesive vehicle composed of gelatin, pectin and carboxymethyl cellulose in a liquid petrolatum polyethylene base intended to maintain medication at the site of application in the mouth for prolonged periods) has recently been introduced for the treatment of recurrent ulcerative stomatitis, erosive lichen planus, denture dermatitis, aphthous stomatitis, black hairy tongue, mucosal erythema multiforme and mucosal lupus erythematosus. It is advised that a thin coating, ¼ inch or less, be applied to the lesion two or three times daily after meals.

**Intralesional Therapy**

A fine suspension of corticosteroid (e.g. triamcinolone acetonide) is injected slowly into the superficial layers of the dermis in usually 0.1 ml amounts at sites 1 cm. apart at weekly intervals. This form of treatment has been recommended for the following conditions:

- Lichen simplex chronicus
- Cysts of acne vulgaris
- Localised psoriasis
- Chronic discoid lupus erythematosus (see, however, under Local Application)
- Granuloma annulare
- Sarcoid
- Hypertrophic lichen planus
- Necrobiosis lipoidica diabeticorum
- Pretibial myxoedema
- Penile plaques of Peyronie's disease
- Nail dystrophies (from psoriasis, lichen planus etc.) (Gerstein, 1962)

Unfortunately, the effects tend to be temporary and dermal atrophy, and occasionally ulceration, may occur. Some systemic effect may be exerted and therefore due care must be taken in the selection of cases.

**Corticotropin**

Pituitary corticotropin, a polypeptide consisting of 39 amino-acids linked together, can only be administered by injection and has now largely been replaced by the orally effective corticosteroids which possess obvious advantages.

The therapeutic and side effects are very largely the same, but it produces a clinical response in a shorter time than an equivalent amount of corticosteroid and the effects wear off less rapidly than those of cortisol when the drug is discontinued. Cortisone can be regulated more accurately than corticotropin, the effects of which are more liable to fluctuation and presuppose a normally responsive adrenal cortex.

For temporary maximal stimulation 60 units of
Acthar gel 12 hourly (for not more than 2 days) and for moderate stimulation 40 units can be given.

For practical purposes the use of corticotrophin is largely confined to initiating a therapeutic response and to activating the adrenal cortex prior to discontinuing steroid therapy. In the latter case 20–40 units of Acthar gel by intramuscular injection twice weekly for three to four weeks may be given.

In some cases of severe life-threatening dermatoses where a state of apparent refractoriness to even very large doses of corticosteroids appears to have been reached, their partial substitution or supplementation by appropriately spaced injections of corticotrophin sometimes appears to be of value.

It is evident that though the introduction of adrenal corticosteroids has brought an addition of the first magnitude to the dermatological armamentarium, it has in no way over-simplified the management of diseases of the skin.

REFERENCES


WILLIAMS, R. S. (1959): Triamcinolone Myopathy, Ibid., i, 698.